BCL2L1 and neoplasm: Our findings collectively suggest that, even when successfully addressing the inherent chemotherapy resistance mediated by BCL-xL, cancer-associated fibroblasts (CAFs) in the tumor microenvironment will still contribute to the development of acquired chemotherapy resistance.